These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12865895)

  • 21. The influence of the tricyclic antidepressant amitriptyline on periodic limb movements during sleep.
    Goerke M; Rodenbeck A; Cohrs S; Kunz D
    Pharmacopsychiatry; 2013 May; 46(3):108-13. PubMed ID: 23293012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
    Marco AD; Appiah-Kubi LS; Chaudhuri KR
    Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists.
    Del Dotto P; Gambaccini G; Caneparo D; Berti C; Bernardini S; Bonuccelli U
    Neurol Sci; 2003 Oct; 24(3):170-1. PubMed ID: 14598071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
    Inzelberg R; Nisipeanu P; Rabey JM; Orlov E; Catz T; Kippervasser S; Schechtman E; Korczyn AD
    Neurology; 1996 Sep; 47(3):785-8. PubMed ID: 8797480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
    Utsumi H;
    Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
    Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N
    Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy.
    Katayama S
    Eur Neurol; 2001; 46 Suppl 1():11-7. PubMed ID: 11741098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC; Appiah-Kubf LS; Chaudhuri KR
    Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cabergoline in the treatment of Parkinson's disease].
    Pastor P; Tolosa E
    Neurologia; 2003 May; 18(4):202-9. PubMed ID: 12721865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The validity of the PAM-RL device for evaluating periodic limb movements in sleep and an investigation on night-to-night variability of periodic limb movements during sleep in patients with restless legs syndrome or periodic limb movement disorder using this system.
    Kobayashi M; Namba K; Ito E; Nishida S; Nakamura M; Ueki Y; Furudate N; Kagimura T; Usui A; Inoue Y
    Sleep Med; 2014 Jan; 15(1):138-43. PubMed ID: 24269130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
    Hutton JT; Koller WC; Ahlskog JE; Pahwa R; Hurtig HI; Stern MB; Hiner BC; Lieberman A; Pfeiffer RF; Rodnitzky RL; Waters CH; Muenter MD; Adler CH; Morris JL
    Neurology; 1996 Apr; 46(4):1062-5. PubMed ID: 8780092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
    Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leg movements during wakefulness in restless legs syndrome: time structure and relationships with periodic leg movements during sleep.
    Ferri R; Manconi M; Plazzi G; Bruni O; Cosentino FI; Ferini-Strambi L; Zucconi M
    Sleep Med; 2012 May; 13(5):529-35. PubMed ID: 22341907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of high-dose cabergoline in Parkinson's disease.
    Odin P; Oehlwein C; Storch A; Polzer U; Werner G; Renner R; Shing M; Ludolph A; Schüler P
    Acta Neurol Scand; 2006 Jan; 113(1):18-24. PubMed ID: 16367894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time structure of leg movement activity during sleep in attention-deficit/hyperactivity disorder and effects of levodopa.
    Ferri R; Bruni O; Novelli L; Picchietti MA; Picchietti DL
    Sleep Med; 2013 Apr; 14(4):359-66. PubMed ID: 23415543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaching disturbed sleep in late Parkinson's Disease: first step toward a proposal for a revised UPDRS.
    Askenasy JJ
    Parkinsonism Relat Disord; 2001 Oct; 8(2):123-31. PubMed ID: 11489677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
    Shiraishi M; Kamo T; Hotta M; Nemoto S; Oshima J; Sugihara H; Yasaki S; Kawakami M; Takahashi Y; Shimojo S
    J Neural Transm (Vienna); 2004 Jun; 111(6):725-32. PubMed ID: 15168219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
    Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
    Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.